|
序 列 ： |
The synthetic peptide used to raise the antibody Cat. No. 200177 is selected from a sequence within the C-term region of human OCRL1. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended. |
| 分 子 式 ： |
C79H138N30O26S2 |
|
分 子 量 ： |
1988.2 g/mol |
|
純 度 ： |
Purity > 80% by HPLC |
|
形 態(tài) ： |
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking e |
|
溶 解： |
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile. |
|
保存條件 ： |
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C. |
| 產(chǎn)品鏈接 ： |
http://www.ABBIOTEC.com/peptides/ocrl1-peptide |
|
產(chǎn)品說明 ： |
|
| 產(chǎn)品描述 ： |
Inositol polyphosphate 5-phosphatase (OCRL1) converts phosphatidylinositol 4,5-biphosphate to phosphatidylinositol 4-phosphate. The enzyme also converts inositol 1,4,5-trisphosphate to inositol 1,4-bisphosphate and inositol 1,3,4,5-tetrakisphosphate to inositol 1,3,4-trisphosphate. The enzyme is involved in lysosomal membrane trafficking by regulating the specific pool of phosphatidylinositol 4,5-bisphosphate that is associated with lysosomes. Defects in OCRL1 are the cause of Lowe syndrome, a multisystem disorder affecting eyes, nervous system and kidney, and Dent disease type 2, a renal disease. |
|
